Stereoselective pharmacokinetics of bisoprolol after intravenous and oral administration in Beagle dogs

被引:15
作者
Horikiri, Y
Suzuki, T
Mizobe, M
机构
[1] Pharmaceutics Research Laboratory, Tanabe Seiyaku Company, Ltd., Yodogawa-ku, Osaka 532, 16-89
关键词
D O I
10.1021/js960453v
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The stereoselective pharmacokinetics of bisoprolol, a highly beta(1)-selective adrenoceptor blocking agent, was studied in dogs. After intravenous and oral administration of the racemate, there was a difference in the plasma concentration between S(-)- and R(+)-bisoprolol. The area under the curve (AUC) of concentration versus time of S(-)-bisoprolol was similar to 1.5 times higher than that of R(+)-bisoprolol, and the elimination half-life of S(-)-bisoprolol was similar to 1.4 times longer than that of R(+)-bisoprolol. However, no differences were observed in the volume of distribution, absolute bioavailability, and renal clearance between the two enantiomers. The plasma protein binding of S(-)-bisaprolol was also the same as that of the R(-)-isomer. No chiral inversion or enantiomer-enantiomer interaction was observed, when enantiomers were solely administered via the intravenous route. The comparison of the oxidative metabolic rate of two enantiomers using dog liver microsomes demonstrated that the metabolite was more slowly formed from S(-)- than from R(+)-bisoprolol. Consequently, we concluded that the stereoselective difference in the metabolic clearance between S(-)- and R(+)-bisoprolol caused the difference in the disposition of bisoprolol enantiomers.
引用
收藏
页码:560 / 564
页数:5
相关论文
共 25 条
[1]   BIAS IN PHARMACOKINETICS AND CLINICAL-PHARMACOLOGY [J].
ARIENS, EJ ;
WUIS, EW .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 42 (04) :361-363
[2]  
BUHRING KU, 1986, J CARDIOVASC PHARM, V8, pS21
[3]   STEREOSPECIFIC EVALUATION OF SOTALOL PHARMACOKINETICS IN A RAT MODEL - EVIDENCE SUGGESTING AN ENANTIOMERIC INTERACTION [J].
CARR, RA ;
PASUTTO, FM ;
FOSTER, RT .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1994, 15 (02) :109-120
[5]   DOSE PROPORTIONALITY OF BISOPROLOL ENANTIOMERS IN HUMANS AFTER ORAL-ADMINISTRATION OF THE RACEMATE [J].
DUTTA, A ;
LANC, R ;
BEGG, E ;
ROBSON, R ;
SIA, L ;
DUKART, G ;
DESJARDINS, R ;
YACOBI, A .
JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 34 (08) :829-836
[6]   KINETICS AND METABOLISM OF (+)-BUFURALOL, (-)-BUFURALOL AND (+/-)-BUFURALOL [J].
FRANCIS, RJ ;
EAST, PB ;
LARMAN, J .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1982, 23 (06) :529-533
[7]  
HAEUSLER G, 1986, J CARDIOVASC PHARM, V8, pS2
[8]  
HORIKIRI Y, UNPUB BIOL PHARM B
[9]   STEREOSELECTIVE RENAL CLEARANCE OF PINDOLOL IN HUMANS [J].
HSYU, PH ;
GIACOMINI, KM .
JOURNAL OF CLINICAL INVESTIGATION, 1985, 76 (05) :1720-1726
[10]   ENANTIOSELECTIVE ASPECTS OF DRUG-ACTION AND DISPOSITION - THERAPEUTIC PITFALLS [J].
JAMALI, F ;
MEHVAR, R ;
PASUTTO, FM .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1989, 78 (09) :695-715